SS-31 (Elamipretide) Protocol Guide
SS-31 (Elamipretide, also known as Bendavia and MTP-131) is a mitochondria-targeted tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It selectively concentrates in the inner mitochondrial membrane by binding to cardiolipin, stabilizing cristae architecture, optimizing electron transport chain efficiency, reducing reactive oxygen species, and restoring ATP production. SS-31 has advanced through multiple clinical trials for Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related macular degeneration, receiving FDA Fast Track and Orphan Drug designations.
Protocol Overview
- Compound
- SS-31 (Elamipretide / Bendavia / MTP-131)
- Category
- Mitochondria-Targeted Peptide
- Mechanism
- Binds cardiolipin on inner mitochondrial membrane, stabilizes cristae, optimizes ETC complex interactions, reduces ROS, restores ATP synthesis
- Sequence
- D-Arg-Dmt-Lys-Phe-NH2 (4 amino acids, cell-permeable)
- Half-Life
- ~4 hours (subcutaneous)
- Vial Size
- 40mg lyophilized powder (typical)
- Route
- Subcutaneous injection
- Frequency
- Once daily
- Cycle Length
- 4-12 weeks
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Conservative | 20 mg | Once daily | Subcutaneous | 4-8 weeks |
| Standard (Clinical) | 40 mg | Once daily | Subcutaneous | 8-12 weeks |
| Weight-Based | 0.25 mg/kg | Once daily | Subcutaneous | 4-12 weeks |
| Acute (IV Research) | 0.05 mg/kg/hr | Continuous infusion | Intravenous | Single session |
Note: The 40mg daily subcutaneous dose is the most studied in clinical trials (TAZPOWER, ReCLAIM, MMPOWER). Weight-based dosing at 0.25 mg/kg is an alternative approach for individualized protocols.
Reconstitution Instructions
Materials Needed
- SS-31 40mg lyophilized vial
- Bacteriostatic water (2mL)
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water
- Inject slowly down the vial wall
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 20 mg/mL
| Dose | Volume (2mL recon) | Insulin Syringe |
|---|---|---|
| 10 mg | 0.50 mL | 50 units |
| 20 mg | 1.00 mL | 100 units (full syringe) |
| 40 mg | 2.00 mL | Full vial (use 1mL syringe x2) |
Administration Guide
Injection Sites
- Primary: Abdomen (2 inches from navel)
- Alternate: Anterior thigh (outer quadrant)
- Alternate: Upper arm (deltoid region)
- Rotate injection sites daily
- Avoid areas with bruising or scarring
Timing & Storage
- Timing: Morning administration preferred
- With food: Can be administered regardless of meals
- Storage (lyophilized): Room temperature or refrigerate
- Storage (reconstituted): Refrigerate 2-8°C, use within 28 days
- Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site reactions (redness, swelling, pain) - most common
- Headache (mild, transient)
- Nausea (uncommon)
- Fatigue (paradoxical, usually resolves)
SS-31 has demonstrated a favorable safety profile in Phase II/III clinical trials with most adverse events being mild injection site reactions.
Precautions
- Monitor renal function (eGFR) at baseline and periodically
- Clinical trial exclusions include severe hepatic impairment
- Not recommended during pregnancy or breastfeeding
- May interact with other mitochondrial-targeted compounds
Stacking Recommendations
Compatible Compounds
- NAD+ precursors (NMN/NR): Complementary mitochondrial support via different pathways
- MOTS-c: Mitochondrial-derived peptide for metabolic optimization
- CoQ10: Electron transport chain cofactor support
- Humanin: Another mitochondrial-derived peptide for cytoprotection
- PQQ: Mitochondrial biogenesis support
Popular Stacks
- Mito Optimization: SS-31 40mg/day + NAD+ + CoQ10
- Longevity Stack: SS-31 + MOTS-c + Humanin
- Energy Recovery: SS-31 + PQQ + Alpha-lipoic acid
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Basic Panel | CBC, CMP | Baseline, Week 6, Week 12 |
| Mitochondrial | Lactate, pyruvate, CoQ10 levels | Baseline, Week 6 |
| Oxidative Stress | 8-OHdG, F2-isoprostanes, MDA | Baseline, Week 6 |
| Cardiac (if applicable) | NT-proBNP, troponin, BNP | Baseline, Week 6, Week 12 |
| Renal Function | eGFR, BUN, creatinine | Baseline, Week 4, Week 8 |
Mitochondrial biomarkers (lactate/pyruvate ratio) provide the most relevant tracking data for SS-31 protocols. Oxidative stress markers help quantify ROS reduction.
Related Tools & Resources
Frequently Asked Questions
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane. It stabilizes cristae structure, optimizes electron transport chain efficiency, reduces ROS production, and restores ATP synthesis in dysfunctional mitochondria.
There is no validated human dose for this compound; the following is a commonly cited research convention, not a validated protocol. The standard SS-31 research protocol uses 0.25-1.0 mg/kg administered subcutaneously once daily. Most clinical trials have used 40mg/day subcutaneous for adults. Protocol duration is typically 4-12 weeks depending on the research objective.
SS-31 has been studied in clinical trials for Barth syndrome, primary mitochondrial myopathy, age-related macular degeneration, heart failure, and renal ischemia-reperfusion injury. It has received FDA Fast Track and Orphan Drug designations for Barth syndrome.